CA057-001 (SUCCESSOR-1)

About this trial

The SUCCESSOR-1 trial is a Phase 3, randomised, open-label study evaluating the efficacy and safety of mezigdomide (CC-92480) in combination with bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib, and dexamethasone (PVd) in patients with relapsed or refractory multiple myeloma (RRMM). Eligible participants must have received one to three prior lines of therapy, including prior lenalidomide exposure, with at least a minimal response to at least one prior regimen. Key exclusions include prior treatment with mezigdomide or pomalidomide and disease progression on a proteasome inhibitor unless refractory only in the first line. The primary endpoint is progression-free survival (PFS), with secondary endpoints assessing overall survival (OS), overall response rate (ORR), and safety outcomes.

Patient Profile

The SUCCESSOR-1 trial is a Phase 3 clinical study focusing on individuals with relapsed or refractory multiple myeloma—a type of blood cancer that has returned or not responded after treatment. The trial aims to compare the effectiveness and safety of a new drug combination: mezigdomide, bortezomib, and dexamethasone, against an existing treatment regimen of pomalidomide, bortezomib, and dexamethasone. Eligible participants are adults who have received one to three prior treatments for multiple myeloma, including a regimen containing lenalidomide, and have shown at least a minimal response to at least one prior therapy. Individuals who have previously been treated with mezigdomide or pomalidomide, or those whose disease progressed during or shortly after treatment with a proteasome inhibitor (except under specific conditions), are not eligible for this study.

Where’s this trial being run?

Cork University Hospital, St James’s Hospital, and University Hospital Galway

Can I join this study / trial?

The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.

Why not Print this page and bring it with you. It will help your doctor and research team advise you.

Print this page

For more detailed information

Click Here

Questions?

Here’s a list of questions you may have for your doctor or local cancer research team.

Questions

---

Summary Data

Name:	CA057-001 (SUCCESSOR-1)
Number:	23-20
Full Title:	CA057-001: a phase 3, two-stage, randomized, multicenter, open-label study comparing mezigdomide (cc-92480), bortezomib and dexamethasone (MEZIVD) versus pomalidomide, bortezomib and dexamethasone (PVD)in subjects with relapsed or refractory multiple myeloma (RRMM): Successor-1

Principal Investigator:	Prof Patrick Hayden
Type:	Industry Sponsored
Sponsor:	BMS
Recruitment Started:	Global: Sept 2022 Ireland: Sept 2023

Global Recruitment Target:	800
Ireland Recruitment Target:	13